Research location
Boulogne
France
Advertisement
Research activity in Boulogne
FranceCureCurrent currently publishes aggregate city-level research activity for this location: 32 trials and 32 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Boulogne
32 linked trials · page 1 of 1Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)NCT06937905 · 2026-02-06 · 1 site observation
RECRUITING
Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung CancerNCT06656598 · 2025-11-07 · 1 site observation
RECRUITING
A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)NCT06053099 · 2024-01-22 · 1 site observation
RECRUITING
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCNCT06162221 · 2024-01-18 · 1 site observation
RECRUITING
Individual Factors Associated With Care Pathways Delays in Breast Cancer in Hauts-de-France.NCT07475325 · 2026-04-20 · 1 site observation
ACTIVE_NOT_RECRUITING
Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & ChemotherapyNCT05781308 · 2023-04-26 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)NCT05200481 · 2022-05-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)NCT04621188 · 2021-03-19 · 1 site observation
ACTIVE_NOT_RECRUITING
Immunotherapy in Patient With Poor General ConditionNCT04108026 · 2020-10-14 · 1 site observation
COMPLETED
Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)NCT01817192 · 2020-09-11 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR MutationNCT04233021 · 2020-07-16 · 1 site observation
COMPLETED
Prevention of HIV in "Île-de-France"NCT03113123 · 2017-05-03 · 1 site observation
UNKNOWN
Genetic, Neurophysiological and Psychological Predictive Factors of Chronic Neuropathic Pain After Surgery for Breast CancerNCT02944721 · 2016-11-01 · 1 site observation
WITHDRAWN
Pharmacokinetic Study of the Association of Amoxicillin / Clavulanic Acid to Obese AdultsNCT02571959 · 2015-07-24 · 1 site observation
COMPLETED
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLCNCT02273375 · 2015-02-24 · 1 site observation
COMPLETED
Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK RearrangementsNCT02727335 · 2014-05-01 · 1 site observation
COMPLETED
Strategies for Maintenance Therapies in Advanced Non Small Cell Lung CancerNCT01631136 · 2012-07-01 · 1 site observation
COMPLETED
Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFRNCT01556191 · 2012-05-15 · 1 site observation
COMPLETED
French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular TestingsNCT01700582 · 2012-04-01 · 1 site observation
COMPLETED
Fibrosis a New Pathological Actor in Adipose TissueNCT01655017 · 2012-02-08 · 1 site observation
COMPLETED
French Biological Observatory on Lung Cancer in Never SmokersNCT01465854 · 2011-11-01 · 1 site observation
COMPLETED
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque PsoriasisNCT01241591 · 2010-11-01 · 1 site observation
COMPLETED
EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac Function in Patients With Iron deficiencY and Chronic Heart FailureNCT00821717 · 2008-12-01 · 1 site observation
TERMINATED
A Rheumatoid Arthritis Study to Assess Early Response to Abatacept+MTX as Defined by Improvement of Synovitis Measures by Power Doppler UltrasonographyNCT00767325 · 2008-12-01 · 1 site observation
COMPLETED
Adjuvant Pazopanib in Stage I NSCLCNCT00775307 · 2008-11-01 · 1 site observation
COMPLETED
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.NCT00615134 · 2008-01-01 · 1 site observation
COMPLETED
NSCLC Relapse Therapy After Surgery and Peri-operative ChemotherapyNCT00535275 · 2007-09-01 · 1 site observation
TERMINATED
Sensitivity of Echography in ArthritisNCT00444691 · 2007-03-01 · 1 site observation
UNKNOWN
Adaptation Dose of Enoxaparin in Moderate Renal Failure Patients With Acute Coronary SyndromeNCT00412802 · 2006-12-01 · 1 site observation
COMPLETED
A Study of Epoetin Beta (NeoRecormon) in Anemic Participants With Diabetes and Chronic Renal Failure Who Are Not on DialysisNCT02827266 · 2005-10-01 · 1 site observation
COMPLETED
Efficacy, and Safety Study of Optimized Background Antiretroviral Regimen (OB) in Combination With Enfuvirtide in the Treatment-Experienced Participants With Human Immunodeficiency Virus-1 (HIV-1) InfectionNCT02733419 · 2004-12-01 · 1 site observation
COMPLETED
Tezosentan in Acute Heart FailureNCT00525707 · 2003-04-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.